Increasing Prevalence Of Neurological Disorders Driving Growth In The Market Due To Advancements In Diagnosis And Neural Repair Therapies: A Key Catalyst Accelerating Nerve Growth Factor Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Nerve Growth Factor Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for nerve growth factor has seen robust growth in the past few years. The market value is expected to rise from $1.11 billion in 2024 to $1.19 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth include a rising number of traumatic brain injuries, a surge in neurodegenerative diseases, more investment in research and development, growing awareness of nerve regrowth treatments, and an increase in the occurrence of peripheral neuropathy.

Nerve Growth Factor Market Size Forecast: What's the Projected Valuation by 2029?
Expectations are high for robust expansion in the nerve growth factor market size in the coming years, with projections indicating growth to "$1.59 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. This predicted surge in the forecast period could be linked to factors such as an escalating demand for biopharmaceuticals, a higher frequency of autoimmune neurological disorders, more concentration on research into neuroinflammation, rising interest in AI-facilitated drug discovery, and increased inclination towards NGF-oriented therapies among consumers. The forecast period also anticipates significant trends like biotechnology advancement, customized medicine methodologies, innovative systems for drug delivery, regulatory approvals, and the creation of nerve growth factor (NGF) antibodies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nerve-growth-factor-global-market-report

What Are the Drivers Transforming the Nerve Growth Factor Market?
The nerve growth factor market is predicted to significantly expand due to the rising incidence of neurological disorders. Such disorders, which affect the brain, spinal cord, and nerves, are attributable to structural, biochemical, or electrical malfunctions. A contributing factor to their increasing presence is an ageing population coupled with advancements in diagnostic technology, which enhance detection and documentation of these ailments. The role of nerve growth factor (NGF) is integral to the preservation, survival, and regeneration of neurons, positioning it as a vital tool in counteracting this spike in neurological disorders by stimulating neural repair and possibly decelerating the progression of such diseases. As an illustration, projections from the Australian Institute of Health and Welfare for September 2024 suggest that dementia cases (a neurological disorder) in Australia will increase from around 411,100 in 2023 to approximately 849,300 by 2058. Consequently, this surge in neurological disorders is fuelling the growth of the nerve growth factor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22070&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Nerve Growth Factor Market?
The nerve growth factor market is witnessing significant advancements with top companies focusing on the development of sophisticated products like nerve growth factor (NGF) monoclonal antibodies to inhibit NGF. The goal of these advancements is to offer effective pain alleviation. NGF monoclonal antibodies, a type of biological medication, aim to target and neutralize the nerve growth factor to prevent receptor interaction, thereby decreasing pain and inflammation in the nerves. They also play a role in controlling pain signals and the survival of nerve cells. A prime example came in February 2022, when Akeso, Inc., a biopharmaceutical firm based in China, launched AK115, a humanized IgG1 monoclonal antibody which has been given the green light by China's National Medical Products Administration to start clinical trials for pain management strategies, including treatment for cancer pain. AK115 is engineered to prevent interactions between NGF and receptors, with the objective of providing pain relief. It also aims at ensuring long-term safety, non-addictiveness, and enhanced efficacy for cancer sufferers who show resistance to opioids. The analgesic product seeks to provide enduring and non-addictive pain management, particularly for cancer patients who are resistant to opioids, thereby elevating their quality of life.

Which Segments in the Nerve Growth Factor Market Offer the Most Profit Potential?
The nerve growth factor market covered in this report is segmented -

1) By Type: Alpha-Nerve Growth Factor (NGF), Beta-Nerve Growth Factor (NGF), Gamma-Nerve Growth Factor (NGF), Other Types
2) By Agents: Cenegermin, Other Agents
3) By Indication: Neurodegenerative Disorders, Spinal Cord Injuries, Eye Disorders, Epithelial Diseases, Tissue Healing, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Alpha-Nerve Growth Factor (α-NGF): Natural Alpha-NGF, Recombinant Alpha-NGF, Synthetic Alpha-NGF, Alpha-NGF For Research Applications
2) By Beta-Nerve Growth Factor (β-NGF): Human Beta-NGF, Animal-Derived Beta-NGF, Recombinant Beta-NGF, Therapeutic Beta-NGF, Research-Grade Beta-NGF
3) By Gamma-Nerve Growth Factor (γ-NGF): Natural Gamma-NGF, Recombinant Gamma-NGF, Synthetic Gamma-NGF, Gamma-NGF for Neurodegenerative Research
4) Other Types: Hybrid NGF Molecules, NGF Mimetics, NGF Gene Therapy-Based Products, NGF-Infused Biomaterials

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22070&type=smp

Which Firms Dominate the Nerve Growth Factor Market by Market Share and Revenue in 2025?
Major companies operating in the nerve growth factor market are Pfizer Inc., AstraZeneca Plc, Eli Lilly & Company, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals Inc., Genetech, Dompé farmaceutici S.p.A., Promega Corporation, Akeso Inc, CUSABIO TECHNOLOGY LLC, Staidson Beijing BioPharmaceuticals, Biocare Medical LLC, Beike Biotechnology, Enzo Life Sciences Inc., Genexis Biotech Pvt. Ltd., Mimetogen Pharmaceuticals, Alomone Labs, MimeTech Srl, Herantis Pharma, Prospec-Tany Technogene Ltd., PainCeptor Pharma

Which Regions Offer the Highest Growth Potential in the Nerve Growth Factor Market?
Asia-Pacific was the largest region in the nerve growth factor market in 2024. The regions covered in the nerve growth factor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22070

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.